Publications by authors named "Chunrong Jin"
Article Synopsis
- Monoclonal antibodies like recaticimab target PCSK9 to effectively lower LDL cholesterol levels, offering an alternative to more frequent treatments due to its long-acting nature.
- The study evaluated recaticimab's effectiveness and safety in patients with nonfamilial hypercholesterolemia and low-to-moderate atherosclerotic cardiovascular disease risk, comparing various dosing strategies.
- Results showed significant LDL-C reductions (up to 52.8%) compared to placebo, with safety profiles similar to that of placebo, suggesting recaticimab may provide a flexible treatment option for patients.
Alternative splicing (AS) and RNA-binding proteins (RBPs) have been implicated in various cardiovascular diseases. Yet, a comprehensive understanding of their role in myocardial ischemia-reperfusion injury (MIRI) remains elusive. We aimed to identify potential therapeutic targets for MIRI by studying genome-wide changes in AS events and RBPs.
View Article and Find Full Text PDFPurpose: Recently, a "U" hazard ratio curve between resting left ventricular ejection fraction (LVEF) and prognosis has been observed in patients referred for routine clinical echocardiograms. The present study sought to explore whether a similar "U" curve existed between resting LVEF and coronary flow reserve (CFR) in patients without severe cardiovascular disease (CVD) and whether impaired CFR played a role in the adverse outcome of patients with supra-normal LVEF (snLVEF, LVEF ≥ 65%).
Methods: Two hundred ten consecutive patients (mean age 52.
Objective: To evaluate the effects and adverse reactions of amiodarone and sotalol in treatment of atrial fibrillation.
Methods: One hundred and two patients with atrial fibrillation, 56 males and 46 females, aged 56 +/- 11, were randomized into 2 equal groups: amiodarone group, taking amiodarone 600 mg/d for 7 days, 400 mg/d for 7 days, 200 mg/d for 7 days, and then 200 mg/d as maintenance dosage if conversion to sinus rhythm occurred; and sotalol group, taking sotalol 40-80 mg/d for one week, 160 mg/d for 2 weeks and then 40-80 mg/d as maintenance dosage if conversion to sinus rhythm occurred. If the cardiac rhythm failed to be converted to sinus rhythm after three week the medication was stopped.